Last reviewed · How we verify
V920 Consistency Lot B
V920 is a vaccine designed to protect against COVID-19 by inducing an immune response against the SARS-CoV-2 virus.
V920 is a vaccine designed to protect against COVID-19 by inducing an immune response against the SARS-CoV-2 virus. Used for Prevention of COVID-19.
At a glance
| Generic name | V920 Consistency Lot B |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
V920 works by introducing a piece of the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body produce antibodies to fight the virus. This immune response can provide protection against COVID-19 and potentially reduce the severity of symptoms if the individual is exposed to the virus.
Approved indications
- Prevention of COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V920 Consistency Lot B CI brief — competitive landscape report
- V920 Consistency Lot B updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI